Synergistic drug combinations against the in vitro replication of Coxsackie B1 virus

Antiviral Research

Volumn 62, Issue 1, 2004, Pages 9-19

  Nikolaeva Glomb, Lubomira ^a   Galabov, Angel S ^a  

^a INSTITUTE OF MICROBIOLOGY   (Bulgaria)

Author keywords

Coxsackievirus B1; Drug combinations; Synergy

Indexed keywords

2 ALPHA HYDROXYBENZYLBENZIMIDAZOLE; ANTIVIRUS AGENT; ARILDONE; DISOXARIL; ENVIROXIME; FENTICLOR; N PHENYL N' 3 HYDROXYPHENYLTHIOUREA; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; COXSACKIE VIRUS B; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; ENTEROVIRUS; NONHUMAN; POLIOMYELITIS VIRUS 1; PRIORITY JOURNAL; VIRUS REPLICATION; VIRUS STRAIN;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CELL LINE; DRUG COMBINATIONS; DRUG SYNERGISM; ENTEROVIRUS B, HUMAN; HUMANS; ISOXAZOLES; KETONES; PHENYLTHIOUREA; PYRIMIDINES; VIRUS REPLICATION;

COXSACKIEVIRUS; ENTEROVIRUS; HUMAN POLIOVIRUS 1;

EID: 1542719076     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2003.11.001     Document Type: Article

References (40)

1. Andries K., Dewindt B., Snoeks J., Wouters L., Moereels H., Lewi P.J., Janssen P.A. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and different pathogenicity. J. Virol. 64:1990;1117-1123.
2. Caliguiri L.A., McSharry J.J., Lawrence G.W. Effect of arildone on modifications of poliovirus in vitro. Virology. 105:1980;86-93.
3. Carrasco L. Picornavirus inhibitors. Pharmacol. Ther. 64:1994;215-290.
4. Dalakas, M.C., 1995. Enteroviruses and human neuromuscular diseases. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 387-398.
5. DeLong D.C., Reed S.E. Inhibition of rhinovirus replication in an organ culture by a potential antiviral drug. J. Infect. Dis. 141:1980;87-91.
6. Diana G.D., Salvador U.J., Zalay E.S., Carabateas P.M., Williams G.L., Collins J.C., Pancic F. Antiviral activity of some β-diketones. 2. Aryloxyl alkyl diketones. In vitro activity against both RNA and DNA viruses. J. Med. Chem. 20:1977;757-761.
7. Dmitrieva T.M., Agol V.I. Selective inhibition of the synthesis of single-stranded RNA of encephalomyocarditis virus by 2-(α-hydroxybenzyl)- benzimidazole in cell-free systems. Arch Gesamte Virusforsch. 45:1974;17-24.
8. Dulbecco R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc. Natl. Acad. Sci. U.S.A. 38:1952;747.
9. Eggers H.J., Rosenwirth B. Isolation and characterization of an arildone-resistant poliovirus 2 mutant with an altered capsid protein VP1. Antiviral Res. 9:1988;23-36.
10. Eggers H.J., Tamm I. On the mechanism of selective inhibition of enterovirus multiplication by 2-(alpha-hydroxybenzyl)-benzimidazole. Virology. 18:1962;426-438.
11. Fox M.P., Otto M.J., McKinlay M.A. Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug. Antimicrob. Agents Chemother. 30:1986;110-116.
12. Fujioka S., Kitaura Y. Coxsackie B virus infection in idiopathic dilated cardiomyopathy: clinical and pharmacological implications. Biodrugs. 15:2001;791-799.
13. Galabov A.S. Thiourea derivatives as specific inhibitors of picornaviruses. Arzneimittelforschung. 29:1979;1863-1868.
14. Galabov A.S., Dmitrieva T.M. Inhibitory effect of N-phenyl-N′-3- hydroxyphenylthiourea (PTU-23) on the reproduction of encephalomyocarditis virus in Krebs-II cells. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A]. 254:1983;291-305.
15. Galabov A.S., Ginevskaya V.A., Svitkin Yu.V. Effect of N-phenyl-N′-3-hydroxyphenylthiourea (PTU-23) on the protein synthesis in Krebs-II cells infected with encephalomyocarditis virus. Zentralbl. Bakteriol. Mikrobiol. Hyg. [A]. 254:1983;306-317.
16. Galabov A.S., Velichkova E.H. Antiviral activity of N-phenyl-N′- aril- or alkylthiourea derivatives in Coxsackie virus infections in mice. Antimicrob. Agents Chemother. 5:1974;1-8.
17. Heinz B.A., Vance L.M. The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus. J. Virol. 69:1995;4189-4197.
18. Heinz B.A., Vance L.M. Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses. J. Virol. 70:1996;4854-4857.
19. Herrmann E.C. Plaque-inhibition tests for detection of specific inhibitors of DNA containing viruses. Proc. Soc. Exp. Biol. 107:1961;142-145.
20. Loddo B. Development of drug resistance and dependence in viruses. Pharmacol. Ther. 10:1980;431-460.
21. Lonberg-Holm K., Gosser L.B., Kauer J.C. Early alteration of poliovirus in infected cells and its specific inhibition. J. Gen. Virol. 27:1975;329-342.
22. Martino, T.A., Liu, P., Petric, M., Sole, M.J., 1995. Enteroviral myocarditis and dilated cardiomyopathy: a rewiew of clinical and experimental studies. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 291-351.
23. McSharry, J.J., Pancic, F., 1982. Arildone: a β-diketone. In: Came, P.E., Caliguiri, L.A. (Eds.), Handbook of Experimental Pharmacology, vol. 61. Springer-Verlag, Berlin, Heidelberg, pp. 419-444.
24. Muir P., Nicholson F., Illavia S.J., McNeil T.S., Ajetunmobi J.F., Dunn H., Starkey W.G., Reetoo K.N., Cary N.R.B., Parameshwar J., Banatvala J.E. Serological and molecular evidence of enterovirus infection in patients with end-stage dilated cardiomyopathy. Heart. 76:1996;243-249.
25. Nikolaeva L., Galabov A.S. In vitro inhibitory effects of dual combinations of picornavirus replication inhibitors. Acta Virol. 43:1999;303-311.
26. Nikolaeva L., Galabov A.S. Antiviral effect of the combination of enviroxime and disoxaril on Coxsackievirus B1 infection. Acta Virol. 44:2000;73-78.
27. Nikolova I., Galabov A.S. Development of resistance to disoxaril in Coxsackie B1 virus-infected newborn mice. Antiviral Res. 60:2003;35-40.
28. Ninomiya Y., Aoyama M., Umeda I., Suhara Y., Ishitsuka H. Comparative studies on the modes of action of the antirhinovirus agents Ro 09-0410, Ro 09-0179, RMI-15 731, 4′,6-dichloroflavan, and enviroxime. Antimicrob. Agents Chemother. 27:1985;595-599.
29. Otto M.J., Fox M.P., Fancher M.J., Kuhrt M.F., Diana G.D., McKinlay M.A. In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug. Antimicrob. Agents Chemother. 27:1985;883-886.
30. Prichard, M.N., Aseltine, K.R., Shipman Jr., C., 1992. MacSynergy™ II. University of Michigan, Ann Arbor, MI.
31. Prichard, M.N., Aseltine, K.R., Shipman Jr., C., 1993. User's Manual. University of Michigan, Ann Arbor, MI.
32. Prichard M.N., Shipman C. Jr. A three-dimensional model to analyze drug-drug interactions. Antiviral Res. 14:1990;181-205.
33. Rewers, M., Atkinson, M., 1995. The possible role of enteroviruses in diabetes mellitus. In: Rotbart, H.A. (Ed.), Human Enterovirus Infections. ASM Press, Washington, DC, pp. 291-351.
34. Rotbart H.A. Treatment of picornavirus infections. Antiviral Res. 53:2002;83-98.
35. Shimizu H., Agoh M., Agoh Y., Yoshida H., Yoshii K., Yoneyama T., Hagiwara A., Miyamura T. Mutations in the 2C region of poliovirus responsible for altered sensitivity to benzimidazole derivatives. J. Virol. 74:2000;4146-4154.
36. Siegl G., Eggers H.J. Failure of guanidine and 2-(alpha-hydroxybenzyl) benzimidazole to inhibit replication of hepatitis A virus in vitro. J. Gen. Virol. 61:1982;111-114.
37. Siminoff P. A plaque suppression method for the study of antiviral compounds. Appl. Microbiol. 9:1961;66-72.
38. Smith T.J., Kremer M.J., Luo M., Vriend G., Arnold E., Kamer G., Rossmann M.G., McKinlay M.A., Diana G.D., Otto M.J. The site of attachment in human rhinovirus 14 for antiviral agents that inhibit uncoating. Science. 233:1986;1286-1293.
39. Sole M.J., Liu P. Viral myocarditis: a paradigm for understanding the pathogenesis and treatment of dilated cardiomyopathy. J. Am. Coll. Cardiol. 22(Suppl. A):1993;99A-105A.
40. Zeichhardt H., Otto M.J., McKinlay M.A., Willingmann P., Habermehl K.-O. Inhibition of poliovirus uncoating by disoxaril (WIN 51711). Virology. 160:1987;281-285.